JOHNSON & JOHNSON, UAB - financials and debts

Company age: 24 y. 1 mo.

Update

JOHNSON & JOHNSON - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 44,529,884 59,697,553 59,558,274 55,833,754 65,433,124 65,858,678 73,075,066 88,774,602
Profit before tax 1,469,207 3,846,787 1,871,723 3,293,156 2,730,509 3,537,064 3,644,562 2,551,276
Net profit 1,185,949 3,114,453 1,499,896 2,717,870 2,060,591 2,864,227 2,966,450 2,034,469
Equity 12,965,069 16,079,522 17,538,613 20,256,482 22,317,072 25,181,299 8,147,749 10,182,218
Liabilities 10,378,475 7,543,680 13,478,473 17,586,383 17,714,663 15,993,306 18,161,190 38,469,491
Non-current assets 1,238,049 968,754 739,594 491,666 548,800 523,946 491,284 368,363
Current assets 22,070,884 24,081,855 30,348,976 37,519,002 39,563,170 40,809,192 26,042,301 48,491,992
Total assets 23,308,933 25,050,609 31,088,570 38,010,668 40,111,970 41,333,138 26,533,585 48,860,355
Taxes paid
STI taxes - - - - - 2,035,734 2,196,272 2,131,840
Social insurance contributions - - - - - 650,811 741,746 775,117
Financial indicators
Revenue change y/y -0.9% +34.1% -0.2% -6.3% +17.2% +0.7% +11.0% +21.5%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 5.1% 12.4% 4.8% 7.2% 5.1% 6.9% 11.2% 4.2%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 9.1% 19.4% 8.6% 13.4% 9.2% 11.4% 36.4% 20.0%
Profit margin Net profit margin. Shows the overall profitability of the company. 2.7% 5.2% 2.5% 4.9% 3.1% 4.3% 4.1% 2.3%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 3.3% 6.4% 3.1% 5.9% 4.2% 5.4% 5.0% 2.9%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.8 0.5 0.8 0.9 0.8 0.6 2.2 3.8
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 961,077 1,161,054 1,191,165 1,179,587 1,422,459 1,546,585 1,706,034 2,238,013

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

Sales revenue

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

JOHNSON & JOHNSON - Social security debts

From To Debt, €
2026-07-16 2026-07-17 509.34
2026-06-18 2026-06-25 509.34
2026-06-16 2026-06-17 453.76
2026-05-20 2026-05-25 1809.65
2026-05-18 2026-05-19 1516.02
2026-02-18 2026-02-25 138.72
2026-01-16 2026-01-25 76.84

JOHNSON & JOHNSON - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
JOHNSON & JOHNSON, UAB (code 111778459) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €88.77M, up 21.5% year on year and 34.8% over two years, showing a strong top-line expansion. Net profit for 2025 was €2.03M, below the €2.97M recorded in 2024 and €2.86M in 2023, while the profit margin narrowed to 2.3% from 4.1% and 4.3% in the previous two years. This indicates that revenue growth outpaced profitability. At the end of 2025, total assets stood at €48.86M, supported by equity of €10.18M and liabilities of €38.47M. The equity ratio was 20.8%, and debt-to-equity was 3.78. Asset turnover reached 1.82x, ROE was 20.0%, and ROA was 4.2%. Revenue per employee was €2.28M, with profit per employee of €52.2K, indicating high productivity in 2025.